2020
DOI: 10.1093/ofid/ofaa215
|View full text |Cite
|
Sign up to set email alerts
|

Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir

Abstract: Abstract Background Quantitative hepatitis B core-related antigen (qHBcrAg) or antihepatitis B core antibody (qAnti-HBc) could be useful in monitoring liver fibrosis evolution during chronic hepatitis B virus (HBV) infection, yet it has not been assessed in human immunodeficiency virus (HIV)-HBV-coinfected patients undergoing treatment with tenofovir (TDF). Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 41 publications
0
3
0
Order By: Relevance
“…One study in TDF-treated HIV-HBV co-infected individuals has been performed evaluating anti-HBc levels, showing that higher levels of this marker at TDF-treatment initiation were only able to exhibit high specificity in predicting HBeAg-seroclearance [ 89 ]. Although this marker did not perform well in predicting HBeAg-seroclearance, its changes during treatment were associated with sudden decreases liver fibrosis levels [ 106 ]. No evaluation of this marker has been made on HBsAg-seroclearance in the treated, HIV-HBV co-infected population.…”
Section: Surrogate Markers Of Hbv Functional Cure In Hiv-hbv Co-infectionmentioning
confidence: 99%
“…One study in TDF-treated HIV-HBV co-infected individuals has been performed evaluating anti-HBc levels, showing that higher levels of this marker at TDF-treatment initiation were only able to exhibit high specificity in predicting HBeAg-seroclearance [ 89 ]. Although this marker did not perform well in predicting HBeAg-seroclearance, its changes during treatment were associated with sudden decreases liver fibrosis levels [ 106 ]. No evaluation of this marker has been made on HBsAg-seroclearance in the treated, HIV-HBV co-infected population.…”
Section: Surrogate Markers Of Hbv Functional Cure In Hiv-hbv Co-infectionmentioning
confidence: 99%
“…Combining qAnti-HBc with two routine serum parameters, PLT (platelet count) and A/G (albumin to globulin ratio), achieved further improvement of the diagnostic accuracy [ 52 ]. On the other hand, Cruchet et al (2020) did not observe an association of baseline qAnti-HBc level with liver fibrosis evolution in tenofovir-treated HIV/HBV co-infected patients [ 53 ]. Curiously, the increase of qAnti-HBc level was linked with a transition to lower fibrosis levels in these patients.…”
Section: Clinical Utility Of Qanti-hbcmentioning
confidence: 99%
“…[ 19 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ] (prediction of hepatic inflammation grade), refs. [ 50 , 51 , 52 , 53 ] (prediction of fibrosis stage), ref. [ 54 ] (prediction of response after TACE therapy for HCC), ref.…”
Section: Figurementioning
confidence: 99%